首页> 外文期刊>Vaccine >Influenza vaccination in HIV-infected individuals: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety
【24h】

Influenza vaccination in HIV-infected individuals: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety

机译:HIV感染者的流感疫苗接种:与疫苗功效,有效性和安全性相关的证据质量的系统审查和评估

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Influenza infection in HIV-infected individuals is associated with increased severity of illness. We performed a systematic review of the available evidence on efficacy, effectiveness and safety of seasonal influenza vaccination in HIV-infected individuals. Design: Systematic review, meta-analysis and assessment of evidence quality. Methods: Using a previous systematic review as starting point, we searched MEDLINE, EMBASE and Cochrane data base for studies on efficacy, effectiveness or safety of trivalent inactivated influenza vaccines (TIV) in HIV-infected individuals. Evidence quality was assessed for each outcome using the GRADE methodology. Results: Three randomized-controlled trials and three cohort studies were identified, including a total of 1562 HIV-infected individuals. In adults, TIV prevented laboratory-confirmed influenza with a pooled efficacy of 85% (95% CI, 22-97%) (evidence quality: moderate), but no significant effects on other clinical outcomes were observed (evidence quality: moderate to low). One cohort study showed an effectiveness of 71% (95% CI, 44-85%) for prevention of laboratory-confirmed influenza, whereas no effect on influenza-like illness was found. However, risk of bias was high in all observational studies. In children aged 6-59 months, efficacy of TIV in preventing laboratory-confirmed influenza was 11% (95% CI, -30 to 54%) (evidence quality: moderate). Regarding other endpoints, no statistically significant effects were reported (evidence quality: moderate to low). No severe adverse events following influenza vaccination were observed in these studies. Conclusion: This systematic review indicates that TIV is effective in preventing influenza infection in HIV-infected adults but not in young children. For both age-groups, only limited evidence exists for other outcomes, indicating a need for further studies
机译:背景:艾滋病毒感染者的流感感染与疾病严重程度增加有关。我们对HIV感染者季节性流感疫苗接种的有效性,有效性和安全性的可用证据进行了系统的综述。设计:系统审查,荟萃分析和证据质量评估。方法:以先前的系统评价为起点,我们搜索MEDLINE,EMBASE和Cochrane数据库,以研究三价灭活流感疫苗(TIV)在HIV感染者中的功效,有效性或安全性。使用GRADE方法评估每个结局的证据质量。结果:确定了三项随机对照试验和三项队列研究,包括总共1562名HIV感染者。在成人中,TIV以85%(95%CI,22-97%)的综合功效预防了实验室确诊的流感(证据质量:中度),但未观察到对其他临床结局的重大影响(证据质量:中度至低度) )。一项队列研究显示,预防实验室确认的流感的有效率为71%(95%CI,44-85%),而未发现对流感样疾病的影响。但是,在所有观察性研究中偏倚风险都很高。在6-59个月大的儿童中,TIV预防实验室确诊的流感的功效为11%(95%CI,-30至54%)(证据质量:中等)。关于其他终点,未报告有统计学意义的影响(证据质量:中度至低度)。在这些研究中未观察到流感疫苗接种后的严重不良事件。结论:该系统评价表明,TIV可有效预防艾滋病毒感染的成年人的流感感染,但不能预防幼儿。对于这两个年龄组,仅存在有限的其他结果证据,表明需要进一步研究

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号